Posted On: 08/27/2014 9:11:31 AM
Post# of 30066
The Company anticipates addressing a number of matters related to our core programs, including qualitative early revenue guidance for LymPro, progress being made on the Company's Phase 2b initiation with Eltoprazine for PD LID, and next steps toward a first-in-man trial for MANF in orphan ophthalmological indications
Tuesday will be interesting.
Tuesday will be interesting.
(0)
(0)
